New Rx for Multiple Myeloma
Today the U.S. Food and Drug Administration granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma who have received at least three prior treatments.
FDA Approves Farydak for Treatment of Multiple Myeloma
The U.S. Food and Drug Administration today approved Farydak (panobinostat) for the treatment of patients with multiple myeloma.
Rx Combo Slowed Multiple Myeloma
When it comes to treating multiple myeloma, three medications may be better than two.
Mega-Dose of Measles Vaccine Killed Cancer
Multiple myeloma is a cancer that develops in the bone marrow and is considered by many to be incurable. An engineered measles virus, however, may change that.
Rare Diseases You've Never Heard Of
In an effort to help raise awareness about rare diseases, here is an introduction to several rare conditions you might not know existed.
Celebrities Affected by Multiple Myeloma
Multiple myeloma is a blood cancer that affects the body’s plasma cells, a type of blood cell that is responsible for making antibodies that help protect from sickness. Here’s a list of celebrities who’ve been affected by this form of cancer.
How Fast Food Leads to Health Problems
Did you hear that McDonald's is serving breakfast ALL DAY? While that may be fun and convenient, don't forget how fast food affects your health.
Healthy Habits After You Hit 40
Most doctors will say that your 40's are an important time for preventing health problems. Here’s some tips that can help you stay healthy.
Wait, I Didn’t Know That About Blood Cancer!
Since there is no screening test for blood cancers, early detection is a challenge. But advances in blood cancer treatments are helping patients live longer, more fulfilling lives.
FDA Grants Janssen Research & Development Breakthrough Therapy Designation for Daratumumab
Janssen Research & Development, LLC (Janssen) announced the US Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for daratumumab for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are double refractory to a PI and IMiD.